Study finds MPS2 scores are highly reproducible across DRE and non-DRE urine samples alike.
Lynx Dx, a leader in innovative diagnostic solutions, announces the publication of a comprehensive analytical validation study of its flagship test, MyProstateScore 2.0 (MPS2), in the peer-reviewed journal Diagnostics. The results confirm the test’s strong analytical performance in detecting prostate cancer biomarkers from both post-digital rectal exam (DRE) and non-DRE urine samples—solidifying MPS2’s utility across in-office and at-home testing settings.
The publication complements earlier clinical validation studies, including a 2024 study in JAMA Oncology and a 2025 study in the Journal of Urology, both of which demonstrated that MPS2 significantly outperforms PSA-based screening and conventional clinical factor models in identifying patients at risk for clinically significant prostate cancer.
Health Technology Insights: Google Cloud and Ai2 Invest $20Million in Cancer AI Alliance
“This study reinforces the value of MPS2 as a non-invasive diagnostic tool that delivers consistent and precise results,” said Dr. Spencer Heaton, Chief Medical Officer at Lynx Dx. “By demonstrating robust analytical performance, MPS2 continues to be validated as a reliable option for prostate cancer risk assessment across diverse clinical workflows.”
MPS2 is a urine-based test that measures 18 prostate cancer-related biomarkers to assess a man’s risk of harboring clinically significant prostate cancer. The analytical validation showed that all 18 biomarkers met stringent criteria for linearity, precision, and detection sensitivity.
The study, which was based on Clinical Laboratory & Standards Institute guidelines, also confirmed high reproducibility of MPS2 scores and analyte detection with minimal interference from common urinary substances—demonstrating the test’s reliability in real-world conditions.
Health Technology Insights: NPA Tracks the Reorganization of the U.S. Department of Health and Human Services
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
